Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    16899778 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Condition: DIRA
Intervention: Drug: Rilonacept
2 Terminated Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
Conditions: NOMID;   CINCA Syndrome
Intervention: Drug: Canakinumab
3 Suspended Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
Conditions: Nervous System Malformations;   Arthropathy, Neurogenic;   Urticaria;   Papilledema
Intervention:

Indicates status has not been verified in more than two years